{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:11:51Z","timestamp":1780499511557,"version":"3.54.1"},"reference-count":84,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"6","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,3]]},"abstract":"<jats:title>ABSTRACT.<\/jats:title>\n                  <jats:p>\n                    When testing poorly tolerated or long-term treatments, including a run-in phase enhances clinical trial efficiency and internal validity by selecting more adherent participants. This report describes the adherence and tolerance of Colombian participants in EQUITY (a randomized, concealed, parallel-group, placebo-controlled trial testing nifurtimox and benznidazole among\n                    <jats:italic>Trypanosoma cruzi<\/jats:italic>\n                    \u2013seropositive adults without cardiomyopathy). Our design included a 10-day, single-blind, placebo run-in phase. On completion, willing participants reporting good adherence (\u226580%) and tolerance were randomized to any five 120-day, blinded treatments: four with either active medication, each given as 120-day half dose or 60-day full dose (followed\/preceded by a randomly allocated 60-day placebo treatment), or a 120-day placebo. Side effects were compared after the run-in (day 0) between excluded and enrolled participants, and between those randomized to active medications or placebo 20 days after starting each treatment period (days 20\/80). Those excluded (44\/351, 12.5%) more often reported gastrointestinal (15.9\/4.6%), nonspecific (13.7\/4.2%), and musculoskeletal symptoms (9.1\/1.6%) than those randomized. Participants given nifurtimox (\n                    <jats:italic>n<\/jats:italic>\n                    = 84) or benznidazole (\n                    <jats:italic>n<\/jats:italic>\n                    = 86) versus placebo (\n                    <jats:italic>n<\/jats:italic>\n                    = 126) on day 20 reported more nonspecific (15.5\/10.5\/4.8%, respectively) or cutaneous side effects (6.0\/12.8\/3.2%). When starting active treatments (transition OFF\u2013ON,\n                    <jats:italic>n<\/jats:italic>\n                    = 171 and\n                    <jats:italic>n<\/jats:italic>\n                    = 61 in first and second 60-day treatment periods), more participants reported emerging-worsening than receding-ending side effects (49\/13 and 15\/5, respectively). Despite inducing a nocebo effect, the run-in phase highlighted more closely related side effects, strengthening causal inference and informing adherence and tolerance to conventional trypanocides.\n                  <\/jats:p>","DOI":"10.4269\/ajtmh.25-0198","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T18:09:04Z","timestamp":1776794944000},"page":"1148-1156","source":"Crossref","is-referenced-by-count":0,"title":["Value of the Run-In Period to Evaluate the Safety of Conventional Trypanocidal Treatment: A Subanalysis of a Colombian Randomized Clinical Trial"],"prefix":"10.4269","volume":"114","author":[{"given":"Juan Carlos","family":"Villar","sequence":"first","affiliation":[{"name":"Facultad de Ciencias de la Salud, Universidad Aut\u00f3noma de Bucaramanga, Bucaramanga, Colombia;"},{"name":"Subdirecci\u00f3n de Investigaciones, Fundaci\u00f3n Cardioinfantil \u2013 Instituto de Cardiolog\u00eda, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Arango","sequence":"additional","affiliation":[{"name":"Subdirecci\u00f3n de Investigaciones, Fundaci\u00f3n Cardioinfantil \u2013 Instituto de Cardiolog\u00eda, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis David","family":"S\u00e1enz-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Subdirecci\u00f3n de Investigaciones, Fundaci\u00f3n Cardioinfantil \u2013 Instituto de Cardiolog\u00eda, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Camacho","sequence":"additional","affiliation":[{"name":"Subdirecci\u00f3n de Investigaciones, Fundaci\u00f3n Cardioinfantil \u2013 Instituto de Cardiolog\u00eda, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"b1","article-title":"Strategy and Plan of Action for Chagas Disease Prevention, Control and Care.","year":"2010"},{"key":"b2","article-title":"Enfermedad de Chagas."},{"key":"b3","series-title":"Circulation","first-page":"1140","article-title":"Cardiac morbidity and mortality due to Chagas\u2019 disease: Prospective electrocardiographic study of a Brazilian community","volume":"75","author":"Maguire","year":"1987"},{"key":"b4","series-title":"JAMA Netw Open","first-page":"e2015072","article-title":"Risk of chronic cardiomyopathy among patients with the acute phase or indeterminate form of Chagas disease: A systematic review and meta-analysis","volume":"3","author":"Chadalawada","year":"2020"},{"key":"b5","series-title":"Am J Trop Med Hyg","first-page":"10","article-title":"Gastrointestinal manifestations of Chagas disease: A systematic review with meta-analysis","volume":"110","author":"Baldoni","year":"2024"},{"key":"b6","series-title":"Int J Infect Dis","first-page":"196","article-title":"Economic costs of Chagas disease in Colombia in 2017: A social perspective","volume":"91","author":"Olivera","year":"2020"},{"key":"b7","series-title":"BMJ","first-page":"176","article-title":"The world\u2019s most neglected disease","volume":"7357","author":"Yamey","year":"2002"},{"key":"b8","series-title":"Guidelines for the Diagnosis and Treatment of Chagas Disease","year":"2018"},{"key":"b9","series-title":"Lancet Reg Health Am","first-page":"100832","article-title":"Clinical features of Chagas disease progression and severity","volume":"37","author":"Nunes","year":"2024"},{"key":"b10","series-title":"Lancet","first-page":"1407","article-title":"Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection","volume":"348","author":"Sgambatti De Andrade","year":"1996"},{"key":"b11","series-title":"Am J Trop Med Hyg","first-page":"526","article-title":"Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas\u2019 disease","volume":"59","author":"Estani","year":"1998"},{"key":"b12","series-title":"J Am Coll Cardiol","first-page":"939","article-title":"Benznidazole and posaconazole in eliminating parasites in asymptomatic T. cruzi carriers: The STOP-CHAGAS Trial","volume":"69","author":"Morillo","year":"2017"},{"key":"b13","series-title":"Lancet Infect Dis","first-page":"419","article-title":"Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: A proof-of-concept, randomised, placebo-controlled trial","volume":"18","author":"Torrico","year":"2018"},{"key":"b14","series-title":"EClinicalMedicine","first-page":"102972","article-title":"Impact of antiparasitic therapy on cardiovascular outcomes in chronic Chagas disease. A systematic review and meta-analysis","volume":"79","author":"Rassi","year":"2025"},{"key":"b15","first-page":"15","article-title":"TRAENA: Tratamiento con benznidazol en pacientes adultos con enfermedad de Chagas cr\u00f3nica de bajo riesgo - Un ensayo cl\u00ednico aleatorizado en Fase 3.","author":"Riarte","year":"2016"},{"key":"b16","series-title":"N Engl J Med","first-page":"e124","article-title":"Randomized trial of benznidazole for chronic Chagas\u2019 cardiomyopathy","volume":"373","author":"Morillo","year":"2015"},{"key":"b17","series-title":"PLoS Negl Trop Dis","first-page":"e488","article-title":"Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of M\u00e9decins Sans Fronti\u00e8res","volume":"3","author":"Yun","year":"2009"},{"key":"b18","series-title":"Lancet Infect Dis","first-page":"386","article-title":"Efficacy of three benznidazole dosing strategies for adults living with chronic Chagas disease (MULTIBENZ): An international, randomised, double-blind, phase 2b trial","volume":"24","author":"Bosch-Nicolau","year":"2024"},{"key":"b19","series-title":"Acta Trop","first-page":"38","article-title":"Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity","volume":"184","author":"Zingales","year":"2018"},{"key":"b20","series-title":"Enferm Infecc Microbiol Clin","first-page":"535","article-title":"Recomendaciones para el diagn\u00f3stico, seguimiento y tratamiento de laembarazada y del ni\u00f1o con enfermedad de Chagas","volume":"31","author":"Gonz\u00e1lez-Tom\u00e9","year":"2013"},{"key":"b21","series-title":"PLoS Negl Trop Dis","first-page":"e0010386","article-title":"Use of benznidazole to treat chronic Chagas disease: An updated systematic review with a meta-analysis","volume":"16","author":"Crespillo-And\u00fajar","year":"2022"},{"key":"b22","series-title":"Expert Rev Anti Infect Ther","first-page":"157","article-title":"Side effects of benznidazole as treatment in chronic Chagas disease: Fears and realities","volume":"7","author":"Viotti","year":"2009"},{"key":"b23","series-title":"BMJ Open","first-page":"e052897","article-title":"New chemotherapy regimens and biomarkers for Chagas disease: The rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia","volume":"11","author":"Alonso-Vega","year":"2021"},{"key":"b24","series-title":"Drug Saf","first-page":"1035","article-title":"Safety profile of benznidazole in the treatment of chronic Chagas disease: Experience of a referral centre and systematic literature review with meta-analysis","volume":"41","author":"Crespillo-And\u00fajar","year":"2018"},{"key":"b25","series-title":"Antimicrob Agents Chemother","first-page":"6125","article-title":"Toxic profile of benznidazole in patients with chronic Chagas disease: Risk factors and comparison of the product from two different manufacturers","volume":"59","author":"Molina","year":"2015"},{"key":"b26","series-title":"PLoS One","first-page":"e0185033","article-title":"Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease","volume":"12","author":"Olivera","year":"2017"},{"key":"b27","series-title":"Contemp Clin Trials Commun","first-page":"101382","article-title":"Run-in periods and treatment outcomes in asthma trials: A narrative review","volume":"42","author":"Pizzichini","year":"2024"},{"key":"b28","series-title":"Ann Oncol","first-page":"803","article-title":"Statistical controversies in clinical research: Limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events\u2014A meta-analysis","volume":"29","author":"Trone","year":"2018"},{"key":"b29","series-title":"Clin Epidemiol","first-page":"169","article-title":"Randomized clinical trials with run-in periods: Frequency, characteristics and reporting","volume":"11","author":"Laursen","year":"2019"},{"key":"b30","series-title":"Eur J Pain","first-page":"874","article-title":"Measuring expectation of pain: Contingent negative variation in placebo and nocebo effects","volume":"21","author":"Piedimonte","year":"2017"},{"key":"b31","series-title":"Psychiatr Danub","first-page":"100","article-title":"Placebo and nocebo effect: A mini-review.","volume":"26","author":"Po\u017egain","year":"2014"},{"key":"b32","series-title":"Int J Behav Med","first-page":"255","article-title":"The Nocebo effect: A review of contemporary experimental research","volume":"29","author":"Bagari\u0107","year":"2022"},{"key":"b33","series-title":"Trials","first-page":"516","article-title":"Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): Study protocol for a randomised controlled trial","volume":"20","author":"Villar","year":"2019"},{"key":"b34","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.","year":"2017"},{"key":"b35","series-title":"Health Psychol","first-page":"1334","article-title":"A systematic review of factors that contribute to nocebo effects","volume":"35","author":"Webster","year":"2016"},{"key":"b36","series-title":"Trials","first-page":"328","article-title":"Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): Study protocol for a multicenter randomized Phase II non-inferiority clinical trial","volume":"21","author":"Molina-Morant","year":"2020"},{"key":"b37","series-title":"N Engl J Med","first-page":"1899","article-title":"Randomized trial of posaconazole and benznidazole for chronic Chagas\u2019 disease","volume":"370","author":"Molina","year":"2014"},{"key":"b38","series-title":"Cochrane Database Syst Rev","first-page":"CD003463","article-title":"Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection","volume":"2014","author":"Villar","year":"2014"},{"key":"b39","series-title":"Br J Anaesth","first-page":"758","article-title":"Sugammadex hypersensitivity and underlying mechanisms: A randomised study of healthy non-anaesthetised volunteers","volume":"121","author":"de Kam","year":"2018"},{"key":"b40","series-title":"Circulation","first-page":"2996","article-title":"ACC\/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology\/American Heart Association task force on practice guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)\u2013Developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America","volume":"104","author":"Hunt","year":"2001"},{"key":"b41","series-title":"Am J Bioeth","first-page":"22","article-title":"To tell the truth, the whole truth, may do patients harm: The problem of the nocebo effect for informed consent","volume":"12","author":"Wells","year":"2012"},{"key":"b42","series-title":"FMC","first-page":"158","article-title":"Efecto nocebo","volume":"26","author":"Madridejos","year":"2019"},{"key":"b1","article-title":"Strategy and Plan of Action for Chagas Disease Prevention, Control and Care.","year":"2010"},{"key":"b2","article-title":"Enfermedad de Chagas."},{"key":"b3","series-title":"Circulation","first-page":"1140","article-title":"Cardiac morbidity and mortality due to Chagas\u2019 disease: Prospective electrocardiographic study of a Brazilian community","volume":"75","author":"Maguire","year":"1987"},{"key":"b4","series-title":"JAMA Netw Open","first-page":"e2015072","article-title":"Risk of chronic cardiomyopathy among patients with the acute phase or indeterminate form of Chagas disease: A systematic review and meta-analysis","volume":"3","author":"Chadalawada","year":"2020"},{"key":"b5","series-title":"Am J Trop Med Hyg","first-page":"10","article-title":"Gastrointestinal manifestations of Chagas disease: A systematic review with meta-analysis","volume":"110","author":"Baldoni","year":"2024"},{"key":"b6","series-title":"Int J Infect Dis","first-page":"196","article-title":"Economic costs of Chagas disease in Colombia in 2017: A social perspective","volume":"91","author":"Olivera","year":"2020"},{"key":"b7","series-title":"BMJ","first-page":"176","article-title":"The world\u2019s most neglected disease","volume":"7357","author":"Yamey","year":"2002"},{"key":"b8","series-title":"Guidelines for the Diagnosis and Treatment of Chagas Disease","year":"2018"},{"key":"b9","series-title":"Lancet Reg Health Am","first-page":"100832","article-title":"Clinical features of Chagas disease progression and severity","volume":"37","author":"Nunes","year":"2024"},{"key":"b10","series-title":"Lancet","first-page":"1407","article-title":"Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection","volume":"348","author":"Sgambatti De Andrade","year":"1996"},{"key":"b11","series-title":"Am J Trop Med Hyg","first-page":"526","article-title":"Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas\u2019 disease","volume":"59","author":"Estani","year":"1998"},{"key":"b12","series-title":"J Am Coll Cardiol","first-page":"939","article-title":"Benznidazole and posaconazole in eliminating parasites in asymptomatic T. cruzi carriers: The STOP-CHAGAS Trial","volume":"69","author":"Morillo","year":"2017"},{"key":"b13","series-title":"Lancet Infect Dis","first-page":"419","article-title":"Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: A proof-of-concept, randomised, placebo-controlled trial","volume":"18","author":"Torrico","year":"2018"},{"key":"b14","series-title":"EClinicalMedicine","first-page":"102972","article-title":"Impact of antiparasitic therapy on cardiovascular outcomes in chronic Chagas disease. A systematic review and meta-analysis","volume":"79","author":"Rassi","year":"2025"},{"key":"b15","first-page":"15","article-title":"TRAENA: Tratamiento con benznidazol en pacientes adultos con enfermedad de Chagas cr\u00f3nica de bajo riesgo - Un ensayo cl\u00ednico aleatorizado en Fase 3.","author":"Riarte","year":"2016"},{"key":"b16","series-title":"N Engl J Med","first-page":"e124","article-title":"Randomized trial of benznidazole for chronic Chagas\u2019 cardiomyopathy","volume":"373","author":"Morillo","year":"2015"},{"key":"b17","series-title":"PLoS Negl Trop Dis","first-page":"e488","article-title":"Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of M\u00e9decins Sans Fronti\u00e8res","volume":"3","author":"Yun","year":"2009"},{"key":"b18","series-title":"Lancet Infect Dis","first-page":"386","article-title":"Efficacy of three benznidazole dosing strategies for adults living with chronic Chagas disease (MULTIBENZ): An international, randomised, double-blind, phase 2b trial","volume":"24","author":"Bosch-Nicolau","year":"2024"},{"key":"b19","series-title":"Acta Trop","first-page":"38","article-title":"Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity","volume":"184","author":"Zingales","year":"2018"},{"key":"b20","series-title":"Enferm Infecc Microbiol Clin","first-page":"535","article-title":"Recomendaciones para el diagn\u00f3stico, seguimiento y tratamiento de laembarazada y del ni\u00f1o con enfermedad de Chagas","volume":"31","author":"Gonz\u00e1lez-Tom\u00e9","year":"2013"},{"key":"b21","series-title":"PLoS Negl Trop Dis","first-page":"e0010386","article-title":"Use of benznidazole to treat chronic Chagas disease: An updated systematic review with a meta-analysis","volume":"16","author":"Crespillo-And\u00fajar","year":"2022"},{"key":"b22","series-title":"Expert Rev Anti Infect Ther","first-page":"157","article-title":"Side effects of benznidazole as treatment in chronic Chagas disease: Fears and realities","volume":"7","author":"Viotti","year":"2009"},{"key":"b23","series-title":"BMJ Open","first-page":"e052897","article-title":"New chemotherapy regimens and biomarkers for Chagas disease: The rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia","volume":"11","author":"Alonso-Vega","year":"2021"},{"key":"b24","series-title":"Drug Saf","first-page":"1035","article-title":"Safety profile of benznidazole in the treatment of chronic Chagas disease: Experience of a referral centre and systematic literature review with meta-analysis","volume":"41","author":"Crespillo-And\u00fajar","year":"2018"},{"key":"b25","series-title":"Antimicrob Agents Chemother","first-page":"6125","article-title":"Toxic profile of benznidazole in patients with chronic Chagas disease: Risk factors and comparison of the product from two different manufacturers","volume":"59","author":"Molina","year":"2015"},{"key":"b26","series-title":"PLoS One","first-page":"e0185033","article-title":"Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease","volume":"12","author":"Olivera","year":"2017"},{"key":"b27","series-title":"Contemp Clin Trials Commun","first-page":"101382","article-title":"Run-in periods and treatment outcomes in asthma trials: A narrative review","volume":"42","author":"Pizzichini","year":"2024"},{"key":"b28","series-title":"Ann Oncol","first-page":"803","article-title":"Statistical controversies in clinical research: Limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events\u2014A meta-analysis","volume":"29","author":"Trone","year":"2018"},{"key":"b29","series-title":"Clin Epidemiol","first-page":"169","article-title":"Randomized clinical trials with run-in periods: Frequency, characteristics and reporting","volume":"11","author":"Laursen","year":"2019"},{"key":"b30","series-title":"Eur J Pain","first-page":"874","article-title":"Measuring expectation of pain: Contingent negative variation in placebo and nocebo effects","volume":"21","author":"Piedimonte","year":"2017"},{"key":"b31","series-title":"Psychiatr Danub","first-page":"100","article-title":"Placebo and nocebo effect: A mini-review.","volume":"26","author":"Po\u017egain","year":"2014"},{"key":"b32","series-title":"Int J Behav Med","first-page":"255","article-title":"The Nocebo effect: A review of contemporary experimental research","volume":"29","author":"Bagari\u0107","year":"2022"},{"key":"b33","series-title":"Trials","first-page":"516","article-title":"Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): Study protocol for a randomised controlled trial","volume":"20","author":"Villar","year":"2019"},{"key":"b34","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.","year":"2017"},{"key":"b35","series-title":"Health Psychol","first-page":"1334","article-title":"A systematic review of factors that contribute to nocebo effects","volume":"35","author":"Webster","year":"2016"},{"key":"b36","series-title":"Trials","first-page":"328","article-title":"Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): Study protocol for a multicenter randomized Phase II non-inferiority clinical trial","volume":"21","author":"Molina-Morant","year":"2020"},{"key":"b37","series-title":"N Engl J Med","first-page":"1899","article-title":"Randomized trial of posaconazole and benznidazole for chronic Chagas\u2019 disease","volume":"370","author":"Molina","year":"2014"},{"key":"b38","series-title":"Cochrane Database Syst Rev","first-page":"CD003463","article-title":"Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection","volume":"2014","author":"Villar","year":"2014"},{"key":"b39","series-title":"Br J Anaesth","first-page":"758","article-title":"Sugammadex hypersensitivity and underlying mechanisms: A randomised study of healthy non-anaesthetised volunteers","volume":"121","author":"de Kam","year":"2018"},{"key":"b40","series-title":"Circulation","first-page":"2996","article-title":"ACC\/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology\/American Heart Association task force on practice guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)\u2013Developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America","volume":"104","author":"Hunt","year":"2001"},{"key":"b41","series-title":"Am J Bioeth","first-page":"22","article-title":"To tell the truth, the whole truth, may do patients harm: The problem of the nocebo effect for informed consent","volume":"12","author":"Wells","year":"2012"},{"key":"b42","series-title":"FMC","first-page":"158","article-title":"Efecto nocebo","volume":"26","author":"Madridejos","year":"2019"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/114\/6\/article-p1148.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/114\/6\/article-p1148.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/114\/6\/article-p1148.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:16:08Z","timestamp":1780496168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/114\/6\/article-p1148.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":84,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.25-0198","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]}}}